WELCOME TO

Exploiting universal tumor and immune targets to
advance the identification and treatment of cancer

OncoNano Medicine, Inc.

OncoNano Medicine is developing a new class of products that exploit universal cancer and immune therapeutic targets to diagnose and treat cancer. Our product candidates are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery, and T cell activating immunotherapies.

Our core technology is comprised of ultra pH-sensitive polymeric micelles that have been engineered to encapsulate and protect a wide variety of payloads, and selectively release them upon exposure to acidic biological environments within tumors and endosomes. Imaging and therapeutic payloads can be encapsulated
in the micelles for systemic administration to specifically target the acidic tumor microenvironment – a hallmark of all solid tumors (the Warburg effect) – while minimizing exposure to normal tissues. Use of pH as a biomarker for cancer
enables micelles to be applied generally to any solid tumor, regardless of its oncogenic phenotype and has been demonstrated in numerous in vivo models and in patients.

In addition to therapeutic delivery, proprietary micelle compositions are developed to activate Stimulator of Interferon Genes (STING), a ubiquitous immune signaling molecule for T cell therapy of solid tumors. Non-canonical STING activation is achieved through polyvalency in an unprecedented and advantageous manner. The combination of the natural STING ligand cGAMP with STING-activating polymers further synergizes innate immune activation leading to highly efficacious T cell immunity against solid cancers.

Key to the success of OncoNano’s polymeric micelle technology is the molecular cooperativity design that achieves threshold pH sensing and STING activation, thereby enabling high specificity in tumor targeting not possible with conventional therapeutic and imaging approaches.

About Us

OncoNano Overview

  • UT Southwestern spin-out, founded on 2014
  • Pegsitacianine in Phase 2 clinical trials with Fast Track designation from the FDA
  • Well-funded company through Series B financing
  • 3-time CPRIT grant awardee plus NIH/NCI SBIR awardee
  • Published in high impact, peer-reviewed journals
  • Highly experienced management team
  • Scientific Advisory Board consisting of thought leaders in oncology
  • Board of Directors consisting of biotechnology and pharmaceutical veterans
NewsPress Releases
October 14, 2021

Pegsitacianine Demonstrates Tumor-Agnostic Real-Time Surgical Imaging in Phase 2 Study

Update on pH-sensitive fluorescent nanoprobe from late-breaking oral presentation at The World Molecular Imaging Congress…
NewsPress Releases
October 8, 2021

Positive Preclinical Data for ONM-501 at AACR Virtual Conference

OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR Virtual Conference on Tumor Immunology…
NewsPress Releases
September 30, 2021

Present at The American Association for Cancer Research Virtual Conference

OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor…
Questions?

Contact

OncoNano Medicine Inc.

Contact Us

Headquarters

OncoNano Medicine Inc.

181 Grand Ave, Ste 225

Southlake, Texas 76092, US

Media Inquiries: Please direct to Lauren Arnold, MacDougall

Larnold@macbiocom.com

QUICK CONTACT